Avenue Therapeutics, Inc. (ATXI)
Stock Price:
$9.90 USD
0.20 (2.06%)
Updated Jul 8, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
165.16M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-15.88M |
| Shares Out |
16.68M |
| EPS (ttm) |
-0.97 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 8, 2020 |
| Last Price |
$9.90 |
| Previous Close |
$9.70 |
| Change ($) |
0.20 |
| Change (%) |
2.06% |
| Day's Open |
9.72 |
| Day's Range |
9.51 - 9.96 |
| Day's Volume |
46,834 |
| 52-Week Range |
4.96 - 11.83 |
More Stats
| Market Cap |
165.16M |
| Enterprise Value |
158.59M |
| Earnings Date (est) |
Aug 12, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
16.68M |
| Float |
5.55M |
| EPS (basic) |
-0.98 |
| EPS (diluted) |
-0.97 |
| FCF / Share |
-1.39 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
49,287 |
| Short Ratio |
0.94 |
| Short % of Float |
2.03% |
| Beta |
0.20 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
29.24 |
| Revenue |
n/a |
| Operating Income |
-16.18M |
| Net Income |
-15.88M |
| Free Cash Flow |
-22.86M |
| Net Cash |
6.57M |
| Net Cash / Share |
0.39 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-55.47% |
| ROE |
-121.58% |
| ROIC |
-1,619.30% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (2)
| Buy |
2 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$12.50*
(26.26% upside)
Low
12.0
Current: 9.90
High
13.0
Target: 12.50
*Average 12-month price target from 2 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|
| Revenue | - | - | - | - | - |
| Operating Income | -26.27 | -21.64 | -11.42 | -2.38 | -4.84 |
| Net Income | -25.91 | -21.55 | -12.26 | -3.18 | -5.23 |
| Shares Outstanding | 15.72 | 10.24 | 6.63 | 2.86 | 2.70 |
| Earnings Per Share | -1.65 | -2.10 | -1.85 | -1.11 | -1.93 |
| Operating Cash Flow | -26.26 | -18.22 | -6.80 | -1.63 | -0.90 |
| Free Cash Flow | -26.26 | -18.22 | -6.80 | -1.63 | -0.90 |
| Cash & Equivalents | 8.75 | 2.67 | 21.78 | 0.20 | 0.01 |
| Total Debt | - | - | - | 5.87 | 3.87 |
| Net Cash / Debt | 8.75 | 2.67 | 21.78 | -5.68 | -3.85 |
| Assets | 8.92 | 4.53 | 22.17 | 0.20 | 0.01 |
| Liabilities | 2.12 | 5.16 | 2.79 | 8.45 | 5.15 |
| Book Value | 6.80 | -0.63 | 19.38 | -8.25 | -5.14 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Avenue Therapeutics, Inc. |
| Country |
United States |
| Employees |
4 |
| CEO |
Lucy Lu |
Stock Information
| Ticker Symbol |
ATXI |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: ATXI |
| IPO Date |
June 27, 2017 |
Description
Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain. The company was founded in 2015 and is based in New York, New York. Effective as of December 31, 2019, Avenue Therapeutics, Inc. operates as a subsidiary of InvaGen Pharmaceuticals, Inc.